OrbiMed

Activity in this selectionApr 30, 2026 · Apr 1, 2026

By stage

Series C+2

Undisclosed2

Series A1

Series B1

Biotech4

Healthtech2

China3

United States2

Denmark1

6 in this selection

Apr 29

Develops in vivo CAR-T cell therapies for cancer and autoimmune diseases

$50MSeries A+

Role not disclosed

Apr 19

Develops interventional therapies for pulmonary hypertension and heart failure

$100MStrategic

Role not disclosed

Apr 15

Develops highly targeted, small molecule medicines for cancer and rare diseases

$108MSeries C

Role not disclosed

Apr 14

Develops first- and best-in-class antibody-drug conjugates (ADCs) for cancer treatment

$75MSeries C

Role not disclosed

Apr 8

Develops next-generation bispecific ADCs for cancer treatment

$137MSeries B

Role not disclosed

Apr 2

Develops minimally invasive implantable brain-machine interfaces (BMI) for neurological diseases

CN¥500MStrategic

Role not disclosed